• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FLURBIPROFEN Drug Record

  • Summary
  • Interactions
  • Claims
  • FLURBIPROFEN chembl:CHEMBL563 Approved

    Alternate Names:

    STREFEN
    U-27182
    BTS-18322
    ANSAID
    FROBEN
    BTS 18322
    FLURBIPROFEN
    TRANSACT
    FLUBIPROFEN
    CEBUTID
    FROBEN SR
    OCUFEN
    FLURBIPROFENO
    2-(2-FLUOROBIPHENYL-4-YL)PROPANOIC ACID
    ANSAID®
    FLURBIPROFENE
    (+-)-2-FLUORO-ALPHA-METHYL-4-BIPHENYLACETIC ACID
    2-FLUORO-ALPHA-METHYL-(1,1'-BIPHENYL)-4-ACETIC ACID
    FLURBIPROFENUM
    3-FLUORO-4-PHENYLHYDRATROPIC ACID
    FLP
    S-FLURBIPROFEN
    FROBEN®
    rxcui:4502
    drugbank:00712
    chemidplus:5104-49-4
    pubchem.compound:3394
    chembl:CHEMBL563

    Drug Info:

    Drug Class anti-inflammatory agents, non-steroidal
    Year of Approval 1986
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antiinflammatory agent,NSAID
    (5 More Sources)

    Publications:

    Smith et al., 2000, Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (cyclooxygenase-2)., J. Biol. Chem.
    Bayly et al., 1999, Structure-based design of COX-2 selectivity into flurbiprofen., Bioorg. Med. Chem. Lett.
    Hinz et al., 2001, Flurbiprofen enantiomers inhibit inducible nitric oxide synthase expression in RAW 264.7 macrophages., Pharm. Res.
    Basselin et al., 2007, Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats., Neurochem. Res.
    van Haeringen et al., 2000, Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen., J Ocul Pharmacol Ther
    Nivsarkar et al., Cyclooxygenase inhibitors: a novel direction for Alzheimer's management., Pharmacol Rep
    Hewett et al., 2000, Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture., J. Pharmacol. Exp. Ther.
    Kurahashi et al., 2001, Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites., J. Cardiovasc. Pharmacol.
    Klegeris et al., Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity., Neurobiol. Aging
    Dröge et al., Alternative splicing of cyclooxygenase-1 mRNA in the human iris., Ophthalmic Res.
    Rieke et al., 1999, The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors., J. Biol. Chem.
    Wang H et al., 2011, Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen., Biochem Pharmacol
    Ajmone-Cat et al., 2006, Prostaglandin E2 and BDNF levels in rat hippocampus are negatively correlated with status epilepticus severity: no impact on survival of seizure-generated neurons., Neurobiol. Dis.
    McDonald MG et al., 2020, Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People., J Pharmacol Exp Ther
    Lee YJ et al., 2015, Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects., Arch Pharm Res
    Lee CR et al., 2003, Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes., Eur J Clin Pharmacol
  • FLURBIPROFEN   PTGS1

    Interaction Score: 1.52

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    11811354 12392782 12711844 17562170 10358065 19066416 10773011


    Sources:
    ChemblInteractions TEND

  • FLURBIPROFEN   PTGS2

    Interaction Score: 1.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name HCT 1026, NO-flurbiprofen
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    11006278 10091674 11405284 17562170 10977131 19066416 10773011


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND TTD

  • FLURBIPROFEN   UGT2B7

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21856293


    Sources:
    PharmGKB

  • FLURBIPROFEN   BDNF

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16531049


    Sources:
    NCI

  • FLURBIPROFEN   CYP2C9

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    32423989 25712887 12698304


    Sources:
    PharmGKB FDA

  • FLURBIPROFEN   TARDBP

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: FLURBIPROFEN

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1986
    Drug Class anti-inflammatory agents, non-steroidal

    Publications:

  • TdgClinicalTrial: FLURBIPROFEN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiinflammatory agent,NSAID
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: FLURBIPROFEN

    • Version: 14-September-2017

    Alternate Names:
    C508 NCI drug code

    Drug Info:

    Publications:
    Ajmone-Cat et al., 2006, Prostaglandin E2 and BDNF levels in rat hippocampus are negatively correlated with status epilepticus severity: no impact on survival of seizure-generated neurons., Neurobiol. Dis.

  • PharmGKB: flurbiprofen

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lee CR et al., 2003, Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes., Eur J Clin Pharmacol
    McDonald MG et al., 2020, Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People., J Pharmacol Exp Ther
    Lee YJ et al., 2015, Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects., Arch Pharm Res

  • DTC: FLURBIPROFEN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL563 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Flurbiprofen

    • Version: 2020.06.01

    Alternate Names:
    D0A1PX TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL563

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Flurbiprofen

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL563

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21